The aim of this study was to assess the economic impact of the use of granulocyte colony stimulating factor (RHu-G-CSF) in patients treated by autologous bone marrow transplantation (ABMT) for lymphomas.
Demographic, clinical and economic data were collected retrospectively from a random sample of 55 patients in four French centres who underwent ABMT (usual care) without or with administration of RHu-G-CSF over a period of 100 days post-ABMT.
The patients treated with RHu-G-CSF had a shorter period of infection, neutropenia and severe neutropenia (P<0.05) when compared with usual care recipients.
Compared to usual care, the use of G-CSF was associated with a 3% reduction in total cost of care for ABMT over 100 days post-ABMT or US$1316, including RHu-G-CSF cost.
This cost reduction was mainly due to a reduced length of stay in hospital and fewer laboratory tests.
Mots-clés Pascal : Lymphome, Homme, Autogreffe, Cellule hématopoïétique, Cellule souche, Facteur stimulant colonie granulocyte, Traitement associé, Analyse coût, Economie santé, Moelle osseuse, Cytokine, Hémopathie maligne, Lymphoprolifératif syndrome, Greffe, Transfusion, Polypeptide
Mots-clés Pascal anglais : Lymphoma, Human, Autograft, Hematopoietic cell, Stem cell, Granulocyte colony stimulating factor, Combined treatment, Cost analysis, Health economy, Bone marrow, Cytokine, Malignant hemopathy, Lymphoproliferative syndrome, Graft, Transfusion, Polypeptide
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0304322
Code Inist : 002B27D02. Création : 10/04/1997.